CMS and FDA announce RAPID Coverage Pathway to accelerate patient access to life-changing medical devices — neurotech major beneficiary
Summary
CMS and FDA jointly announced the RAPID (Rapid Access to Preventive Interventions for Devices) Coverage Pathway in April 2026, designed to accelerate patient access to life-changing medical devices by compressing the gap between FDA approval and Medicare/Medicaid coverage. The RAPID pathway provides concurrent FDA review and coverage review for breakthrough devices — replacing the sequential process where devices wait 12-24 months after FDA approval for CMS coverage decisions. Neurotech Notables #53 highlighted RAPID as one of the major regulatory changes happening in Washington with significant implications for BCI and neuromodulation companies approaching commercialization.
Why it matters
The CMS-FDA RAPID pathway directly addresses the most cited commercial barrier in neurotech: the 12-24 month gap between FDA approval and Medicare coverage. Without coverage, FDA-approved neuromodulation devices are inaccessible to most patients who cannot pay $20,000-100,000+ out-of-pocket. RAPID concurrent review means clinical trial data that satisfies FDA can simultaneously satisfy CMS — compressing commercialization timelines by 1-2 years for devices like Cognito Spectris, LivaNova RECOVER, and future BCI products.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial